Brief: Medicenna Announces Submission Of Clinical Trial Application In Australia For A Phase 1/2 Study Of MDNA11
23/06/2021 14:29
June 23 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA ANNOUNCES SUBMISSION OF CLINICAL TRIAL
APPLICATION IN
AUSTRALIA FOR A PHASE 1/2 STUDY OF MDNA11
* MEDICENNA THERAPEUTICS CORP - INITIATION OF ABILITY STUDY,
A
FIRST-IN-HUMAN TRIAL, IS EXPECTED IN Q3 OF 2021
* MEDICENNA THERAPEUTICS CORP - PRELIMINARY UPDATE ON
SAFETY,
PK/PD, AND BIOMARKER DATA EXPECTED BY YEAR END
Source text for Eikon: ID:nGNX9C2C7g
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results